Comparative Efficacy of Psilocybin and MDMA in PTSD Treatment: A Systematic Review of Long-Term Outcomes
Berkeley Scientific Journal – November 13, 2025
Source: OpenAlex
Summary
Psychedelics, particularly psilocybin and MDMA, show promising potential in treating PTSD, a condition that affects about 7-8% of the population. Traditional therapies often yield limited success, with only around 30-40% of patients achieving significant improvement. In contrast, studies indicate that psilocybin can lead to symptom reduction in over 60% of participants, while MDMA has demonstrated similar efficacy. These substances promote neural plasticity, paving the way for innovative treatments in psychiatry and enhancing therapeutic outcomes for those grappling with trauma.
Abstract
Highly stressful events can lead to post-traumatic stress disorder (PTSD)-a significant public health concern which existing treatments (e.g., psychotherapy and traditional medications) have shown marginal efficacy for.Psychedelics-alternatively called hallucinogens-are psychoactive substances that cause perception, mood, and cognitive changes.Because they are known for their impact on neuron plasticity and the formation of new connections, researchers are exploring psychedelics' therapeutic potential for PTSD.This review compares psilocybin and MDMA's effectiveness in treating PTSD.